CBG Faculty

Cervico-vaginal self-collection in HIV-infected and uninfected women from Tapajós region, Amazon, Brazil: High acceptability, hrHPV diversity and risk factors Gynecol Oncol. 2018 10; 151(1):102-110. . View in PubMed

Annexin A2 in Virus Infection Front Microbiol. 2018; 9:2954. . View in PubMed

Heterotetrameric annexin A2/S100A10 (A2t) is essential for oncogenic human papillomavirus trafficking and capsid disassembly, and protects virions from lysosomal degradation Sci Rep. 2018 08 03; 8(1):11642. . View in PubMed

Cancer testis antigen Sperm Protein 17 as a new target for triple negative breast cancer immunotherapy Oncotarget. 2017 Sep 26; 8(43):74378-74390. . View in PubMed

A Unique Cellular and Molecular Microenvironment Is Present in Tertiary Lymphoid Organs of Patients with Spontaneous Prostate Cancer Regression Front Immunol. 2017; 8:563. . View in PubMed

Herpes simplex virus downregulation of secretory leukocyte protease inhibitor enhances human papillomavirus type 16 infection J Gen Virol. 2016 Feb; 97(2):422-434. . View in PubMed

Annexin A2 antibodies but not inhibitors of the annexin A2 heterotetramer impair productive HIV-1 infection of macrophages in vitro Virol J. 2016 11 18; 13(1):187. . View in PubMed

Current therapeutic vaccination and immunotherapy strategies for HPV-related diseases Hum Vaccin Immunother. 2016 06 02; 12(6):1418-29. . View in PubMed

A novel murine model for evaluating bovine papillomavirus prophylactics/therapeutics for equine sarcoid-like tumours J Gen Virol. 2015 Sep; 96(9):2764-2768. . View in PubMed

Forced LIGHT expression in prostate tumors overcomes Treg mediated immunosuppression and synergizes with a prostate tumor therapeutic vaccine by recruiting effector T lymphocytes Prostate. 2015 Feb 15; 75(3):280-91. . View in PubMed

Functional analysis of HPV-like particle-activated Langerhans cells in vitro Methods Mol Biol. 2015; 1249:333-50. . View in PubMed

A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies J Transl Med. 2012 Nov 05; 10:218. . View in PubMed

Cancer testes antigens in breast cancer: biological role, regulation, and therapeutic applicability Int Rev Immunol. 2012 Oct; 31(5):302-20. . View in PubMed

Cancer testis antigen, ropporin, is a potential target for multiple myeloma immunotherapy J Immunother. 2011 Jul-Aug; 34(6):490-9. . View in PubMed

Cancer testis antigens: novel biomarkers and targetable proteins for ovarian cancer Int Rev Immunol. 2011 Apr-Jun; 30(2-3):127-37. . View in PubMed

Bovine papillomavirus DNA can be detected in keratinocytes of equine sarcoid tumors Vet Microbiol. 2010 Dec 15; 146(3-4):269-75. . View in PubMed

Expression of LIGHT/TNFSF14 combined with vaccination against human papillomavirus Type 16 E7 induces significant tumor regression Cancer Res. 2010 May 15; 70(10):3955-64. . View in PubMed

Cancer testis antigen vaccination affords long-term protection in a murine model of ovarian cancer PLoS One. 2010 May 12; 5(5):e10471. . View in PubMed

A major role for the minor capsid protein of human papillomavirus type 16 in immune escape J Immunol. 2009 Nov 15; 183(10):6151-6. . View in PubMed

Head and neck squamous cell cancer and the human papillomavirus: summary of a National Cancer Institute State of the Science Meeting, November 9-10, 2008, Washington, DC. Head Neck. 2009 Nov; 31(11):1393-422. . View in PubMed

Down-regulation of proteasomal subunit MB1 is an independent predictor of improved survival in ovarian cancer Gynecol Oncol. 2009 May; 113(2):256-63. . View in PubMed

Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization Prostate. 2009 May 01; 69(6):571-84. . View in PubMed

A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting Immunol Rev. 2008 Apr; 222:316-27. . View in PubMed

AKAP-4: a novel cancer testis antigen for multiple myeloma Br J Haematol. 2008 Feb; 140(4):465-8. . View in PubMed

A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia Gynecol Oncol. 2007 Sep; 106(3):558-66. . View in PubMed

Advances in immunotherapy of multiple myeloma: from the discovery of tumor-associated antigens to clinical trials Int Rev Immunol. 2007 May-Aug; 26(3-4):197-222. . View in PubMed

A NOD/SCID tumor model for human ovarian cancer that allows tracking of tumor progression through the biomarker Sp17 J Immunol Methods. 2007 Apr 10; 321(1-2):86-93. . View in PubMed

Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion Vaccine. 2006 Jun 12; 24(24):5235-44. . View in PubMed

Gamma-radiation upregulates MHC class I/II and ICAM-I molecules in multiple myeloma cell lines and primary tumors In Vitro Cell Dev Biol Anim. 2006 Mar-Apr; 42(3-4):89-95. . View in PubMed

Heterologous papillomavirus virus-like particles and human papillomavirus virus-like particle immune complexes activate human Langerhans cells Vaccine. 2005 Feb 25; 23(14):1720-9. . View in PubMed

Disease-stage variance in functional CD4(+) T-cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus-16 E7 epitopes Clin Cancer Res. 2004 May 15; 10(10):3301-8. . View in PubMed

Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes Vaccine. 2004 Jan 02; 22(3-4):520-7. . View in PubMed

Cure of glioma: a space not yet occupied for the lesion Cancer Invest. 2004; 22(3):479-80. . View in PubMed

Advances in prophylactic cancer vaccine research Expert Rev Anticancer Ther. 2003 Aug; 3(4):537-45. . View in PubMed

Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines Vaccine. 2003 Jul 04; 21(23):3219-27. . View in PubMed

Differential uptake and cross-presentation of human papillomavirus virus-like particles by dendritic cells and Langerhans cells Cancer Res. 2003 Jul 01; 63(13):3478-82. . View in PubMed

Enhanced tumour growth after DNA vaccination against human papilloma virus E7 oncoprotein: evidence for tumour-induced immune deviation Vaccine. 2003 Jun 02; 21(19-20):2506-15. . View in PubMed

CD4+ T cell matters in tumor immunity Int Rev Immunol. 2003 Mar-Apr; 22(2):113-40. . View in PubMed

HPV protein/peptide vaccines: from animal models to clinical trials Front Biosci. 2003 Jan 01; 8:s81-91. . View in PubMed

Advances in immunotherapy for prostate cancer Adv Cancer Res. 2003; 87:159-94. . View in PubMed

Cervical cancer vaccines: recent advances in HPV research Viral Immunol. 2003; 16(2):111-21. . View in PubMed

Emerging strategies in tumor vaccines Curr Opin Oncol. 2002 Nov; 14(6):641-8. . View in PubMed

Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice Cancer Res. 2002 Oct 15; 62(20):5792-9. . View in PubMed

Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells Nat Med. 2002 Sep; 8(9):979-86. . View in PubMed

Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention Intervirology. 2002; 45(4-6):300-7. . View in PubMed

Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines Virology. 2001 Nov 25; 290(2):350-60. . View in PubMed

Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA Cancer Res. 2001 Nov 01; 61(21):7861-7. . View in PubMed

Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine J Immunol. 2001 May 01; 166(9):5366-73. . View in PubMed

A murine model for the effects of pelvic radiation and cisplatin chemotherapy on human papillomavirus vaccine efficacy Clin Cancer Res. 2001 Mar; 7(3 Suppl):876s-881s. . View in PubMed

Cervical cancer vaccines: emerging concepts and developments J Cell Physiol. 2001 Feb; 186(2):169-82. . View in PubMed

A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive Clin Cancer Res. 2000 Sep; 6(9):3406-16. . View in PubMed

Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma J Immunother. 2000 Mar-Apr; 23(2):255-66. . View in PubMed

Effects of TGF-beta on the immune system: implications for cancer immunotherapy Leukemia. 1999 Aug; 13(8):1188-99. . View in PubMed

Chimeric papillomavirus virus-like particles induce a murine self-antigen-specific protective and therapeutic antitumor immune response J Cell Biochem. 1999 May 01; 73(2):145-52. . View in PubMed

Differential binding of viral peptides to HLA-A2 allelesImplications for human papillomavirus type 16 E7 peptide-based vaccination against cervical carcinoma. Eur J Immunol. 1999 04; 29(4):1292-303. . View in PubMed

Differences in the effectiveness of delivery of B- and CTL-epitopes incorporated into the hepatitis B core antigen (HBcAg) c/e1-region Arch Virol. 1999; 144(7):1323-43. . View in PubMed

Active immunization against cancer cells: impediments and advances Semin Oncol. 1998 Dec; 25(6):697-706. . View in PubMed

Efficient direct priming of tumor-specific cytotoxic T lymphocyte in vivo by an engineered APC Cancer Res. 1998 Jul 15; 58(14):3094-100. . View in PubMed

Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells J Immunol. 1998 May 01; 160(9):4449-56. . View in PubMed

Cellular immunity and immunotherapy against deoxyribonucleic acid virus-induced tumors Monaldi Arch Chest Dis. 1998 Apr; 53(2):211-8. . View in PubMed

Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model Proc Natl Acad Sci U S A. 1998 Feb 17; 95(4):1800-5. . View in PubMed

Evidence for and implications of SV40-like sequences in human mesotheliomas and osteosarcomas Dev Biol Stand. 1998; 94:33-40. . View in PubMed

Activation or frustration of anti-tumor responses by T-cell-based immune modulation Semin Immunol. 1997 Oct; 9(5):323-7. . View in PubMed

HIV-1 reverse transcriptase-specific CTL against conserved epitopes do not protect against progression to AIDS J Immunol. 1997 Oct 01; 159(7):3648-54. . View in PubMed

Autoantibodies to p53 in ovarian cancer patients and healthy women: a comparison between whole p53 protein and 18-mer peptides for screening purposes Cancer Lett. 1997 Jun 03; 116(1):93-101. . View in PubMed

Decreased expression of signal-transducing zeta chain in peripheral T cells and natural killer cells in patients with cervical cancer Clin Cancer Res. 1996 Nov; 2(11):1825-8. . View in PubMed

Efficient tumor eradication by adoptively transferred cytotoxic T-cell clones in allogeneic hosts Int J Cancer. 1996 May 29; 66(5):686-91. . View in PubMed

Enhanced tumor outgrowth after peptide vaccinationFunctional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J Immunol. 1996 May 15; 156(10):3911-8. . View in PubMed

An HLA class I peptide-binding assay based on competition for binding to class I molecules on intact human B cellsIdentification of conserved HIV-1 polymerase peptides binding to HLA-A*0301. Hum Immunol. 1995 Dec; 44(4):189-98. . View in PubMed

Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity Nat Med. 1995 Dec; 1(12):1297-302. . View in PubMed

Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors Eur J Immunol. 1995 Sep; 25(9):2638-42. . View in PubMed

Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor J Immunother Emphasis Tumor Immunol. 1995 Aug; 18(2):86-94. . View in PubMed

Cellular immunity against DNA tumour viruses: possibilities for peptide-based vaccines and immune escape Biochem Soc Trans. 1995 Aug; 23(3):692-6. . View in PubMed

Competition inhibition of cytotoxic T-lymphocyte (CTL) lysis, a more sensitive method to identify candidate CTL epitopes than induction of antibody-detected MHC class I stabilization Immunol Lett. 1995 Jul-Aug; 47(1-2):1-8. . View in PubMed

Antigen capture and major histocompatibility class II compartments of freshly isolated and cultured human blood dendritic cells J Exp Med. 1995 Jul 01; 182(1):163-74. . View in PubMed

Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2 Cancer Res. 1995 Jun 15; 55(12):2627-34. . View in PubMed

A computer program for predicting possible cytotoxic T lymphocyte epitopes based on HLA class I peptide-binding motifs Hum Immunol. 1995 May; 43(1):13-8. . View in PubMed

Detailed motifs for peptide binding to HLA-A*0201 derived from large random sets of peptides using a cellular binding assay Hum Immunol. 1995 May; 43(1):1-12. . View in PubMed

CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells J Immunol. 1995 Apr 15; 154(8):3991-8. . View in PubMed

An adenovirus type 5 early region 1B-encoded CTL epitope-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene J Immunol. 1995 Apr 01; 154(7):3396-405. . View in PubMed

Functional and ultrastructural aspects of antigen processing by dendritic cells Adv Exp Med Biol. 1995; 378:227-31. . View in PubMed

Class I MHC-peptide interactions: structural requirements and functional implications Cancer Surv. 1995; 22:37-49. . View in PubMed

Efficient MHC class I-peptide binding is required but does not ensure MHC class I-restricted immunogenicity Mol Immunol. 1994 Dec; 31(18):1391-401. . View in PubMed

Differential effect of transporter Tap 2 gene introduction into RMA-S cells on viral antigen processing Eur J Immunol. 1993 Dec; 23(12):3082-8. . View in PubMed

Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides J Immunother Emphasis Tumor Immunol. 1993 Aug; 14(2):121-6. . View in PubMed

A rapid isolation procedure for dendritic cells from mouse spleen by centrifugal elutriation J Immunol Methods. 1992 Oct 19; 155(1):101-11. . View in PubMed

Cytotoxic T lymphocytes against the antigen-processing-defective RMA-S tumor cell line Eur J Immunol. 1992 Jun; 22(6):1639-42. . View in PubMed

Cytotoxic T lymphocyte therapy of cancer and tumor escape mechanisms Semin Cancer Biol. 1991 Oct; 2(5):347-54. . View in PubMed

Fine peptide specificity of cytotoxic T lymphocytes directed against adenovirus-induced tumours and peptide-MHC binding Int J Cancer Suppl. 1991; 6:90-4. . View in PubMed

Different requirements for the regulation of transplantation tolerance induction for allogeneic versus xenogeneic major histocompatibility complex antigens Hum Immunol. 1990 Nov; 29(3):220-8. . View in PubMed

Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro Cell. 1990 Aug 10; 62(3):563-7. . View in PubMed

Association between the cellular p53 and the adenovirus 5 E1B-55kd proteins reduces the oncogenicity of Ad-transformed cells EMBO J. 1990 Aug; 9(8):2621-9. . View in PubMed

Efficacy of cytotoxic T lymphocytes against virus-induced tumors Cancer Cells. 1990 Apr; 2(4):116-20. . View in PubMed

Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes Cell. 1989 Nov 17; 59(4):603-14. . View in PubMed

Allograft tolerance induction in adult mice associated with functional deletion of specific CTL precursors Transplantation. 1989 Nov; 48(5):844-7. . View in PubMed

Failure or success in the restoration of virus-specific cytotoxic T lymphocyte response defects by dendritic cells J Immunol. 1988 May 01; 140(9):3186-93. . View in PubMed

Dendritic cells and antigen presentation in the regulation of cytotoxic T lymphocyte responses against viruses and transplantation antigens Ann N Y Acad Sci. 1988; 532:280-91. . View in PubMed

Cooperation between cytotoxic and helper T lymphocytes in protection against lethal Sendai virus infectionProtection by T cells is MHC-restricted and MHC-regulated; a model for MHC-disease associations. J Exp Med. 1986 Sep 01; 164(3):723-38. . View in PubMed

Alternative splicing in the mouse H-2Kd gene is not necessary for the classical Kd antigen function Immunogenetics. 1986; 24(4):267-74. . View in PubMed

Abolition of specific immune response defect by immunization with dendritic cells Nature. 1985 Nov 7-13; 318(6041):59-62. . View in PubMed